Affordable CHOICE Act
- Bill Number
- H.R. 7023
- Origin Chamber
- House
- Congress
- 119th Congress, Session 2
- Policy Area
- Health
- Status
- Introduced
- Latest Action
- 2026-01-12: Referred to the House Committee on Energy and Commerce.
- Last Updated
- 2026-06-25T08:08:04Z
AI-Generated Summary
Purpose of the Legislation
The Affordable CHOICE Act (H.R. 7023) aims to amend the Patient Protection and Affordable Care Act (ACA) to create a government-run public health insurance option. This option is designed to increase access to affordable, high-quality health coverage by offering it through the ACA's Health Insurance Marketplaces (Exchanges), promoting competition, value, and stability in the insurance market.
Key Provisions
- Establishment and Offerings:
- The Secretary of Health and Human Services (HHS) must establish the public health insurance option for plan years starting January 1, 2027.
- It will be offered exclusively through the Exchanges as a qualified health plan (QHP), providing bronze, silver, and gold coverage levels (these refer to tiers of benefits and cost-sharing under the ACA).
- The focus is on affordability without reducing care quality or access.
- Administration:
- HHS will directly administer the option, complying with ACA rules on benefits, provider networks, consumer protections, and cost-sharing.
- HHS can contract for administrative tasks (e.g., claims processing) similar to Medicare, but without transferring insurance risk to contractors.
- States may create optional advisory councils with public and provider representatives to recommend improvements in quality, cost control, public awareness, and payment models; HHS can adopt these nationwide.
- Financing:
- Premiums will be set geographically (adjusted for regional cost differences) to fully cover health benefits and administrative costs, with a contingency margin for unexpected expenses; premiums can only vary by age, location, family size, tobacco use, and plan category (per existing ACA rules).
- Provider reimbursement rates will be negotiated by HHS; if no agreement, rates default to Medicare fee-for-service levels (adjusted for new services like well-child visits).
- Prescription drug payments will be negotiated or based on Medicare rates.
- A dedicated Treasury account will handle funds; start-up funding is authorized (to cover initial reserves for 90 days), to be repaid over 10 years starting 2027; additional appropriations are allowed for operations.
- States are prohibited from taxing the option's receipts, similar to Medicare rules.
- Provider Participation:
- HHS sets participation conditions, requiring state licensure or certification.
- Medicare and Medicaid providers automatically participate unless they opt out via an HHS process.
- Non-Medicare/Medicaid providers can apply to join.
- Data Collection:
- HHS must gather data to set premiums and reimbursements, improve quality, and address health disparities (e.g., racial or ethnic differences in care).
Significant Changes to Existing Law
- Adds a new section (1314) to the ACA, creating the public option as a QHP offered directly by HHS, not private insurers.
- Amends ACA definitions to explicitly include the public option as a QHP, ensuring it meets the same standards as private plans (e.g., essential health benefits) while maintaining a "level playing field" without special advantages or disadvantages.
- Introduces negotiation powers for provider and drug payments, with Medicare as a fallback, expanding beyond current ACA mechanisms.
- Authorizes initial federal funding and a repayment structure, differing from fully private QHP financing.
Potential Impacts
- On Citizens: Could lower premiums and increase choices for individuals buying insurance through Exchanges, potentially reducing uninsured rates and improving access to care; may help control costs via competition but could affect private plan pricing.
- On Government Agencies: Places primary responsibility on HHS to design, administer, and finance the option, increasing its role in health insurance; requires new data systems and negotiations, potentially straining resources initially.
- On Providers and Insurers: Providers face new reimbursement negotiations or Medicare-like rates, which are often lower than private insurance; private insurers may experience more competition, possibly leading to market adjustments.
- On International Relations: No direct impacts mentioned or implied.
Main Stakeholders Affected
- Health Care Consumers: Primary beneficiaries, gaining a public alternative for affordable coverage.
- Health Care Providers: Including doctors, hospitals, and pharmacies; affected by participation rules and payment rates.
- Private Health Insurers: Face direct competition from the public option in Exchanges.
- Federal Government (HHS): Responsible for implementation, administration, and funding.
- States: Can influence via advisory councils; Exchanges operators may see enrollment shifts.
- Taxpayers: Fund start-up via appropriations, with repayment from premiums.
Notable Legal, Constitutional, or Political Implications
- Legal: Builds on ACA frameworks (e.g., Exchanges, QHP standards) and Medicare authorities, but introduces novel elements like direct HHS offerings and drug negotiations, which could face challenges over administrative feasibility or anti-trust issues in rate-setting.
- Constitutional: Relies on Congress's commerce clause powers to regulate health insurance markets; no explicit challenges noted, but expands federal involvement in a state-regulated industry.
- Political: Represents a step toward greater public sector role in health care without full single-payer system; could spark debates on government competition with private markets, cost controls, and equity in addressing disparities, potentially influencing future ACA expansions or reforms.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Rep. Schakowsky, Janice D. [D-IL-9]
Cosponsors (6)
Rep. Cohen, Steve [D-TN-9], Del. Norton, Eleanor Holmes [D-DC-At Large], Rep. Johnson, Julie [D-TX-32], Rep. Moore, Gwen [D-WI-4], Rep. Stevens, Haley M. [D-MI-11], Rep. Craig, Angie [D-MN-2]
Recent Actions
- 2026-01-12: Referred to the House Committee on Energy and Commerce.
- 2026-01-12: Introduced in House
- 2026-01-12: Introduced in House
Bill Versions
- Affordable Consumer Health Options and Insurance Competition Enhancement Act — issued 2026-01-12 — PDF (12 pages)